

Vaccine Technologies Market By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant, Conjugate and Subunit Vaccines, Toxoid Vaccines, Others), By Delivery Method (Parenteral, Oral, Nasal), By Type (Monovalent Vaccines, Multivalent Vaccines): Global Opportunity Analysis and Industry Forecast, 2024-2033

Market Report | 2024-12-01 | 348 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$2655.00
- Business User License \$4425.00
- Enterprise License \$7412.00

Report description:

The vaccine technologies market was valued at \$48,460.07 million in 2023 and is estimated to reach \$90,573.02 million by 2033, exhibiting a CAGR of 6.4% from 2024 to 2033.

Vaccine technologies encompass the scientific methods and biotechnological approaches employed to develop vaccines that protect against infectious diseases, cancers, and other health conditions. These technologies have evolved significantly over time, progressing from traditional inactivated and live-attenuated vaccines to innovative platforms such as messenger RNA (mRNA) vaccines, viral vector-based vaccines, and protein subunit vaccines. Thus, vaccine technologies play a pivotal role in safeguarding public health and addressing emerging global health challenges.

The global vaccine technologies market is witnessing robust growth due to alarming rise in global burden of infectious diseases such as influenza and hepatitis. As per a study published in 2023 by the World Health Organization, influenza alone causes 3-5 million severe cases annually, highlighting the need for effective vaccines. In addition, increase in governments investments in vaccine research and manufacturing infrastructure to ensure preparedness for pandemics is notably contributing toward the market growth. Rise in public awareness campaigns and global immunization initiatives by organizations like UNICEF and GAVI have boosted vaccine uptake, further encouraging the development of advanced vaccine technologies. Moreover, rise in outbreaks of zoonotic diseases, including Ebola and avian influenza, highlight the need for vaccine technologies capable of addressing emerging threats. For instance, a study by the World Health Organization revealed that over 60% of emerging infectious diseases globally are zoonoses. However, developing advanced vaccine technologies, such as mRNA or viral vector platforms, requires substantial investment in research, clinical trials, and manufacturing infrastructure, which significantly hampers the market growth. While vaccines are generally safe, rare adverse events can erode public confidence and lead to

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

litigation, thus restraining the market growth. For example, common side effects after pneumococcal conjugate vaccination include redness, swelling, pain at the injection site, fever, loss of appetite, irritability, fatigue, headache, muscle or joint pain, and chills. On the contrary, innovations such as mRNA technology, viral vector platforms, and nanotechnology are revolutionizing vaccine design, improving efficacy and safety. Such developments are expected to open new avenues for the expansion of the global market during the forecast period.□

The vaccine technologies market is segmented into technology, delivery method, type, and region. By technology, the market is classified into live attenuated vaccines, inactivated vaccines, recombinant, conjugate, and subunit vaccines; toxoid vaccines; and others. Depending on delivery method, it is segregated into parenteral, oral, and nasal. On the basis of type, it is divided into monovalent vaccines and multivalent vaccines. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Competitive Analysis□

The key players operating in the vaccine technologies market include Sanofi, Pfizer Inc., Emergent BioSolutions Inc, AstraZeneca, CSL Limited, Sinovac Biotech Ltd., Bavarian Nordic, Chongqing Zhifei Biological Products Co., Ltd., Merck & Co. Inc., GSK Plc., and Bharat Biotech International Limited. These players have adopted product launch, agreement, product approval, and clinical trials their key strategies to strengthen their foothold in the competitive market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine technologies market analysis from 2023 to 2033 to identify the prevailing vaccine technologies market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the vaccine technologies market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global vaccine technologies market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- New Product Development/ Product Matrix of Key Players
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Expanded list for Company Profiles
 - Historic market data
 - Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Key Market Segments
- By Technology
- Live Attenuated Vaccines
 - Inactivated Vaccines
 - Recombinant, Conjugate and Subunit Vaccines
 - Toxoid Vaccines
 - Others
- By Delivery Method
- Parenteral
 - Oral
 - Nasal
- By Type
- Monovalent Vaccines
 - Multivalent Vaccines
- By Region
- North America
 - U.S.
 - Canada
 - Mexico
 - Europe
 - Germany
 - France
 - UK
 - Italy
 - Spain
 - Rest of Europe
 - Asia-Pacific
 - Japan
 - China
 - India
 - Australia
 - South Korea
 - Rest of Asia-Pacific
 - LAMEA
 - Brazil
 - Saudi Arabia
 - South Africa
 - Rest of LAMEA
 - Key Market Players
 - Emergent BioSolutions Inc.
 - CSL Limited
 - GSK plc.
 - Bavarian Nordic
 - Merck & Co Inc

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Pfizer Inc.
- Sinovac Biotech Ltd
- AstraZeneca
- Chongqing Zhifei Biological Products Co., Ltd.
- Sanofi
- Bharat Biotech International Limited

Table of Contents:

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
 - 1.4.1. Primary research
 - 1.4.2. Secondary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top impacting factors
 - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
 - 3.3.1. Moderate bargaining power of suppliers
 - 3.3.2. Moderate threat of new entrants
 - 3.3.3. Moderate threat of substitutes
 - 3.3.4. Moderate intensity of rivalry
 - 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
 - 3.4.1. Drivers
 - 3.4.1.1. Rise in prevalence of infectious diseases
 - 3.4.1.2. Growing trend towards preventive healthcare
 - 3.4.1.3. Government Immunization Programs and Initiatives
 - 3.4.2. Restraints
 - 3.4.2.1. Cold Chain Storage and Logistics Challenges
 - 3.4.3. Opportunities
 - 3.4.3.1. Technological advancement

CHAPTER 4: VACCINE TECHNOLOGIES MARKET, BY TECHNOLOGY

- 4.1. Overview
 - 4.1.1. Market size and forecast
- 4.2. Live Attenuated Vaccines
 - 4.2.1. Key market trends, growth factors and opportunities
 - 4.2.2. Market size and forecast, by region
 - 4.2.3. Market share analysis by country
- 4.3. Inactivated Vaccines
 - 4.3.1. Key market trends, growth factors and opportunities

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Recombinant, Conjugate and Subunit Vaccines
 - 4.4.1. Key market trends, growth factors and opportunities
 - 4.4.2. Market size and forecast, by region
 - 4.4.3. Market share analysis by country
- 4.5. Toxoid Vaccines
 - 4.5.1. Key market trends, growth factors and opportunities
 - 4.5.2. Market size and forecast, by region
 - 4.5.3. Market share analysis by country
- 4.6. Others
 - 4.6.1. Key market trends, growth factors and opportunities
 - 4.6.2. Market size and forecast, by region
 - 4.6.3. Market share analysis by country

CHAPTER 5: VACCINE TECHNOLOGIES MARKET, BY DELIVERY METHOD

- 5.1. Overview
 - 5.1.1. Market size and forecast
- 5.2. Parenteral
 - 5.2.1. Key market trends, growth factors and opportunities
 - 5.2.2. Market size and forecast, by region
 - 5.2.3. Market share analysis by country
- 5.3. Oral
 - 5.3.1. Key market trends, growth factors and opportunities
 - 5.3.2. Market size and forecast, by region
 - 5.3.3. Market share analysis by country
- 5.4. Nasal
 - 5.4.1. Key market trends, growth factors and opportunities
 - 5.4.2. Market size and forecast, by region
 - 5.4.3. Market share analysis by country

CHAPTER 6: VACCINE TECHNOLOGIES MARKET, BY TYPE

- 6.1. Overview
 - 6.1.1. Market size and forecast
- 6.2. Monovalent Vaccines
 - 6.2.1. Key market trends, growth factors and opportunities
 - 6.2.2. Market size and forecast, by region
 - 6.2.3. Market share analysis by country
- 6.3. Multivalent Vaccines
 - 6.3.1. Key market trends, growth factors and opportunities
 - 6.3.2. Market size and forecast, by region
 - 6.3.3. Market share analysis by country

CHAPTER 7: VACCINE TECHNOLOGIES MARKET, BY REGION

- 7.1. Overview
 - 7.1.1. Market size and forecast By Region
- 7.2. North America
 - 7.2.1. Key market trends, growth factors and opportunities
 - 7.2.2. Market size and forecast, by Technology
 - 7.2.3. Market size and forecast, by Delivery Method

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.4. Market size and forecast, by Type
- 7.2.5. Market size and forecast, by country
 - 7.2.5.1. U.S.
 - 7.2.5.1.1. Market size and forecast, by Technology
 - 7.2.5.1.2. Market size and forecast, by Delivery Method
 - 7.2.5.1.3. Market size and forecast, by Type
 - 7.2.5.2. Canada
 - 7.2.5.2.1. Market size and forecast, by Technology
 - 7.2.5.2.2. Market size and forecast, by Delivery Method
 - 7.2.5.2.3. Market size and forecast, by Type
 - 7.2.5.3. Mexico
 - 7.2.5.3.1. Market size and forecast, by Technology
 - 7.2.5.3.2. Market size and forecast, by Delivery Method
 - 7.2.5.3.3. Market size and forecast, by Type
- 7.3. Europe
 - 7.3.1. Key market trends, growth factors and opportunities
 - 7.3.2. Market size and forecast, by Technology
 - 7.3.3. Market size and forecast, by Delivery Method
 - 7.3.4. Market size and forecast, by Type
 - 7.3.5. Market size and forecast, by country
 - 7.3.5.1. Germany
 - 7.3.5.1.1. Market size and forecast, by Technology
 - 7.3.5.1.2. Market size and forecast, by Delivery Method
 - 7.3.5.1.3. Market size and forecast, by Type
 - 7.3.5.2. France
 - 7.3.5.2.1. Market size and forecast, by Technology
 - 7.3.5.2.2. Market size and forecast, by Delivery Method
 - 7.3.5.2.3. Market size and forecast, by Type
 - 7.3.5.3. UK
 - 7.3.5.3.1. Market size and forecast, by Technology
 - 7.3.5.3.2. Market size and forecast, by Delivery Method
 - 7.3.5.3.3. Market size and forecast, by Type
 - 7.3.5.4. Italy
 - 7.3.5.4.1. Market size and forecast, by Technology
 - 7.3.5.4.2. Market size and forecast, by Delivery Method
 - 7.3.5.4.3. Market size and forecast, by Type
 - 7.3.5.5. Spain
 - 7.3.5.5.1. Market size and forecast, by Technology
 - 7.3.5.5.2. Market size and forecast, by Delivery Method
 - 7.3.5.5.3. Market size and forecast, by Type
 - 7.3.5.6. Rest of Europe
 - 7.3.5.6.1. Market size and forecast, by Technology
 - 7.3.5.6.2. Market size and forecast, by Delivery Method
 - 7.3.5.6.3. Market size and forecast, by Type
- 7.4. Asia-Pacific
 - 7.4.1. Key market trends, growth factors and opportunities
 - 7.4.2. Market size and forecast, by Technology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.3. Market size and forecast, by Delivery Method
- 7.4.4. Market size and forecast, by Type
- 7.4.5. Market size and forecast, by country
 - 7.4.5.1. Japan
 - 7.4.5.1.1. Market size and forecast, by Technology
 - 7.4.5.1.2. Market size and forecast, by Delivery Method
 - 7.4.5.1.3. Market size and forecast, by Type
 - 7.4.5.2. China
 - 7.4.5.2.1. Market size and forecast, by Technology
 - 7.4.5.2.2. Market size and forecast, by Delivery Method
 - 7.4.5.2.3. Market size and forecast, by Type
 - 7.4.5.3. India
 - 7.4.5.3.1. Market size and forecast, by Technology
 - 7.4.5.3.2. Market size and forecast, by Delivery Method
 - 7.4.5.3.3. Market size and forecast, by Type
 - 7.4.5.4. Australia
 - 7.4.5.4.1. Market size and forecast, by Technology
 - 7.4.5.4.2. Market size and forecast, by Delivery Method
 - 7.4.5.4.3. Market size and forecast, by Type
 - 7.4.5.5. South Korea
 - 7.4.5.5.1. Market size and forecast, by Technology
 - 7.4.5.5.2. Market size and forecast, by Delivery Method
 - 7.4.5.5.3. Market size and forecast, by Type
 - 7.4.5.6. Rest of Asia-Pacific
 - 7.4.5.6.1. Market size and forecast, by Technology
 - 7.4.5.6.2. Market size and forecast, by Delivery Method
 - 7.4.5.6.3. Market size and forecast, by Type
- 7.5. LAMEA
 - 7.5.1. Key market trends, growth factors and opportunities
 - 7.5.2. Market size and forecast, by Technology
 - 7.5.3. Market size and forecast, by Delivery Method
 - 7.5.4. Market size and forecast, by Type
 - 7.5.5. Market size and forecast, by country
 - 7.5.5.1. Brazil
 - 7.5.5.1.1. Market size and forecast, by Technology
 - 7.5.5.1.2. Market size and forecast, by Delivery Method
 - 7.5.5.1.3. Market size and forecast, by Type
 - 7.5.5.2. Saudi Arabia
 - 7.5.5.2.1. Market size and forecast, by Technology
 - 7.5.5.2.2. Market size and forecast, by Delivery Method
 - 7.5.5.2.3. Market size and forecast, by Type
 - 7.5.5.3. South Africa
 - 7.5.5.3.1. Market size and forecast, by Technology
 - 7.5.5.3.2. Market size and forecast, by Delivery Method
 - 7.5.5.3.3. Market size and forecast, by Type
 - 7.5.5.4. Rest of LAMEA
 - 7.5.5.4.1. Market size and forecast, by Technology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.5.5.4.2. Market size and forecast, by Delivery Method

7.5.5.4.3. Market size and forecast, by Type

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction

8.2. Top winning strategies

8.3. Product mapping of top 10 player

8.4. Competitive dashboard

8.5. Competitive heatmap

8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Sanofi

9.1.1. Company overview

9.1.2. Key executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Pfizer Inc.

9.2.1. Company overview

9.2.2. Key executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.2.7. Key strategic moves and developments

9.3. Emergent BioSolutions Inc.

9.3.1. Company overview

9.3.2. Key executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Bavarian Nordic

9.4.1. Company overview

9.4.2. Key executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.4.7. Key strategic moves and developments

9.5. Bharat Biotech International Limited

9.5.1. Company overview

9.5.2. Key executives

9.5.3. Company snapshot

9.5.4. Operating business segments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
- 9.6. Chongqing Zhifei Biological Products Co., Ltd.
 - 9.6.1. Company overview
 - 9.6.2. Key executives
 - 9.6.3. Company snapshot
 - 9.6.4. Operating business segments
 - 9.6.5. Product portfolio
 - 9.6.6. Business performance
 - 9.6.7. Key strategic moves and developments
- 9.7. Sinovac Biotech Ltd
 - 9.7.1. Company overview
 - 9.7.2. Key executives
 - 9.7.3. Company snapshot
 - 9.7.4. Operating business segments
 - 9.7.5. Product portfolio
 - 9.7.6. Business performance
 - 9.7.7. Key strategic moves and developments
- 9.8. AstraZeneca
 - 9.8.1. Company overview
 - 9.8.2. Key executives
 - 9.8.3. Company snapshot
 - 9.8.4. Operating business segments
 - 9.8.5. Product portfolio
 - 9.8.6. Business performance
 - 9.8.7. Key strategic moves and developments
- 9.9. CSL Limited
 - 9.9.1. Company overview
 - 9.9.2. Key executives
 - 9.9.3. Company snapshot
 - 9.9.4. Operating business segments
 - 9.9.5. Product portfolio
 - 9.9.6. Business performance
 - 9.9.7. Key strategic moves and developments
- 9.10. GSK plc.
 - 9.10.1. Company overview
 - 9.10.2. Key executives
 - 9.10.3. Company snapshot
 - 9.10.4. Operating business segments
 - 9.10.5. Product portfolio
 - 9.10.6. Business performance
 - 9.10.7. Key strategic moves and developments
- 9.11. Merck & Co Inc
 - 9.11.1. Company overview
 - 9.11.2. Key executives
 - 9.11.3. Company snapshot
 - 9.11.4. Operating business segments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.11.5. Product portfolio
- 9.11.6. Business performance
- 9.11.7. Key strategic moves and developments

**Vaccine Technologies Market By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant, Conjugate and Subunit Vaccines, Toxoid Vaccines, Others),
By Delivery Method (Parenteral, Oral, Nasal), By Type (Monovalent Vaccines,
Multivalent Vaccines): Global Opportunity Analysis and Industry Forecast, 2024-2033**

Market Report | 2024-12-01 | 348 pages | Allied Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$2655.00
	Business User License	\$4425.00
	Enterprise License	\$7412.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-03-10

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com